Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 236 shares of common stock on May 6, 2025, to cover withholding tax liabilities related to vested restricted stock units.

Summary

• On May 6, 2025, Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 236 shares of the company's common stock.
• The sale was executed at a price of $7.12 per share.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021.
• The purpose of the sale was to cover withholding tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Paulson directly owns 82,503 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 6

Explanation: The document describes a routine transaction (stock sale for tax obligations) by an executive, which is neither particularly positive nor negative. The sentiment is neutral.

Management Comments

• The sale does not represent a discretionary trade by the reporting person.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of the company's performance or future prospects.

Key Dates

Keywords

Karyopharm Therapeutics, Richard Paulson, stock sale, Form 4, insider trading, restricted stock units, withholding tax, automatic sale plan